Tradestie Institutional Equity Comparison Engine
ICCC vs CSBR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ICCC Overall Edge
ICCC Captures Institutional Edge (2โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Growth & Margin, Momentum & Technical while CSBR counters with relative strength in Valuation. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus CSBR at 46.8x Forward P/E and -1.5% operating margin (+8.8% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CSBR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
CSBR
ICCC N/M vs CSBR 46.8x Fwd P/E
Growth & Margin Winner
ICCC
Op Margin 15.2% vs -1.5% ยท YoY +11.5% vs +8.8%
Momentum & Technical Winner
ICCC
1Y +88.8% vs -31.9% ยท 52W Pos 91% vs 4%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ICCC
NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap
$97.7M
1M Return
+6.23%
1Y Return
+88.76%
Forward P/E
N/M
Unified AI Score
43.8 / 100
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
CSBR
NASDAQ
Champions Oncology, Inc.
Biological Products, (No Disgnostic Substances)
$4.68
-0.53% 1D
Market Cap
$65.5M
1M Return
-0.43%
1Y Return
-31.88%
Forward P/E
46.8x
Unified AI Score
44.4 / 100
HOLD
Tech 46.0
Fund 49.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ICCC +88.76%
CSBR -31.88%
Spread: +120.93 pp (ICCC Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ICCC TTM Op. Margin: 15.2%
CSBR TTM Op. Margin: -1.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICCC vs CSBR. Trailing 12-month operating profitability (ICCC 15.2% vs CSBR -1.5%) and valuation multiples (ICCC N/M vs CSBR 46.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ICCC | CSBR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $97.7M | $65.5M | Larger Scale | ICCC |
| Trailing P/E Ratio Valuation | 56.6x | 22.9x | Lower Multiple | CSBR |
| Forward P/E Ratio Valuation | N/M | 46.8x | Lower Multiple | CSBR |
| Revenue Growth (YoY) Growth | +11.5% | +8.8% | Higher Growth | ICCC |
| Operating Margin (TTM) Profitability | 15.2% | -1.5% | Higher Margin | ICCC |
| Net Profit Margin Profitability | 2.6% | -1.9% | Higher Margin | ICCC |
| Return on Equity (ROE) Capital Efficiency | 2.6% | -28.4% | Higher ROE | ICCC |
| 52-Week Range Position Momentum | 91% ($5โ$12) | 4% ($5โ$8) | Stronger Trend | ICCC |
| Beta / 30D Volatility Risk Regime | 0.24ฮฒ ยท 46% Vol | 0.36ฮฒ ยท 24% Vol | Lower Realized Risk | CSBR |
| Unified Institutional Score Composite Signal | 43.8 / 100 (HOLD) | 44.4 / 100 (HOLD) | Higher Composite | CSBR |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ICCC vs CSBR Buy Guide
ICCC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CSBR
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ICCC nor CSBR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.